Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 181Breast Neoplasms 154Prostatic Neoplasms 144Lung Neoplasms 139Glioblastoma 119Head and Neck Neoplasms 115Squamous Cell Carcinoma of Head and Neck 110Rectal Neoplasms 107Lymphoma 101Esophageal Neoplasms 100Pancreatic Neoplasms 76Esophageal Squamous Cell Carcinoma 71Leukemia 70Neoplasms 67Brain Neoplasms 67Lymphoma, Follicular 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Lymphoma, Non-Hodgkin 62Lymphoma, Large B-Cell, Diffuse 58Hodgkin Disease 56Uterine Cervical Neoplasms 53Central Nervous System Neoplasms 53Leukemia, Lymphocytic, Chronic, B-Cell 52Gliosarcoma 51Sarcoma 50Colorectal Neoplasms 50Neoplasm Metastasis 45Lymphoma, Large-Cell, Immunoblastic 45Glioma 44Burkitt Lymphoma 43

Interventions

Gemcitabine 2Cystectomy 2Cisplatin 2transplatin 1pembrolizumab 1pegfilgrastim 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Chemoradiotherapy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Infiltrating Bladder Urothelial Carcinoma × Radiotherapy × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡